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Abstract
Colistin emerged in the last decade as a savior for the treatment of 
critically septic patients who suffer MDR-GNB infections. This develop-
ment came in time with the drying new antibacterial pipelines. MDR-
GNB became problematic in ICU’s including MDR Acinetobacter spp., 
Pseudomonas aeruginosa, and carbapenemase-producing Enterobac-
teriaecae (CPE). With the resurgence of wide colistin prescription espe-
cially in ICU’s, awareness on when to switch to this reintroduced drug 
is required. Recently, it is observed that there are differences between 
the past dosages and the currently proposed dosages. Nephrotoxicity 
and neurotoxicity are observed to be less than what was published in 
the past. This may be due to more pure preparations and attention 
to other drug therapies that are employed in the critically ill patients 
residing the ICU’s. However,randomized control studies are still lack-
ing to shed light on its efficacy and safety. Agreement is still looming 
on dosages, and monotherapy of colistin versus its combination with 
other agents.
Keywords: Colistimethate sodium, Colistin, Multidrug resistant gram-
negative bacteria, Pharmacokinetics, Monotherapy & combination 
therapy.
Introduction
New antimicrobials are urgently needed, including extended-spectrum 
β-lactamase (ESBL) producers and carbapenemase-producing entero-
bacteriaecae (CPE). MDR-GNB became prevalent in hospitals and 
nursing homes, they carry solitary or multiple genotypic resistance 
patterns [1,2]. In a retrospective multicenter study from Detroit, Michi-
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gan, a cohort of 1441 patients were queried for 
their microbiological data from Oakwood Health-
care System database. Acinetobacter baumannii 
resistance rates were found to have had escalated 
between 2003 - 2008 to imipenem and ampicil-
lin/sulbactam from 1.8% to 33.1% (P < 0.001), as 
did MDR-Acinetobacter from 0.0% to 13.6% (P 
< 0.001) [3]. Risk groups are patients residing in 
ICU’s, on mechanical ventilation, prolonged hospi-
talization and prolonged administration of antibiot-
ics, especially carbapenems [4]. MDR-Acinetobacter 
infections causes more death among patients than 
sensitive organisms [5]. The same phenomenon was 
evident in MDR-Pseudomonas aeruginosa bactere-
mia, when mortality was observed to be earlier (P 
= 0.011) and higher 30-days mortality probably due 
to more of inappropriate therapy [6]. With the wide-
spread of MDR-GNB and shortage of the current 
antimicrobials’ spectrum, their inadequate coverage 
became evident; meanwhile the antimicrobial pipe 
line is becoming dry from new compounds [7, 8]. 
The need for an almost previouslyabandoned anti-
microbial agent like colistin resurfaced as its benefi-
cial re-experience in the treatment of patients with 
MDR-GNB became evident.
Colistin clinical chemistry and doses
Colistin is an antibiotic originally isolated by Koyama 
et al. in 1950 from the microorganism Bacillus poly-
myxa (Earlier:colistinus). It was introduced as an ef-
fective antimicrobial agent against a range of GNB; 
it kept widely used till 1970s, when other alterna-
tive agents became available. Polymyxins isolated 
as fermentation products were five; A, B, C, D and 
E. Polymyxin E, initially prepared as colistin sulfate, 
initially used as topical powder for bacterial skin in-
fection and orally for bowel decontamination. Later 
colistin was available as a prodrug; colistimethate 
sodium (CMS). The active ingredients are E1 and 
E2, which is available for parenteral and inhalation 
routes [9,10].  
Intravenous colistin is now considered for the treat-
ment of infections caused by MDR-GNB when con-
firmed by susceptibility testing anda feasible option 
for treating patients with infections due to GNB that 
are susceptible in vitro to other antimicrobial agents 
butthose agents are clinically ineffective.Colistin has 
been administered less commonly by aerosol ize-
droute, especially in treating patients with cystic 
fibrosis; hitherto,developments of significantprob-
lems with colistin-resistant Pseudomonas aerugino-
sa strains have not been worrisome after more than 
a decade of experience in the treatment of patients 
with cystic fibrosis, and the rate of development of 
resistance to colistin was slower than that to aero-
solized tobramycin [11].
Mechanism of action and resistance
Most data came from the work on Polymyxin B 
which has anactivity almost similar to colistin; poly-
myxins were found to interact with the outer mem-
brane of GNB, it competitively displace the divalent 
cations Mg+2 and Ca+2 from the negatively charged 
phosphate groups of membrane lipid. Insertion of-
polymyxins disrupts the outer membrane releasing 
lipopolysaccharides, however,colistin has anti-endo-
toxinactivity, the significance of this mechanism in 
preventing the endotoxin’s ability to induce shock 
through the release of cytokines is not clear [11]. 
Resistance can occur through alteration of the bac-
terial outer membrane and efflux pump through 
potassium system,complete cross resistant between 
polymyxin B and colistin is documented [11].Poly-
myxins have no activity against gram-positive bac-
teria and anaerobes, but are active against most 
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clinically relevant Enterobacteriaceae except Proteus 
spp., Providencia spp., and Morganellamorganii. Lac-
tose non-fermenter species like P. aeruginosa and 
Acinetobacter spp. are susceptible, including major-
ity of MDR isolates. Stenotrophomonas maltophilia 
is usually susceptible with the exception of some 
resistant strains. Burkholderia cepacia complex is 
resistant, as well as Serratia marcescens [12].
Pharmacokinetics/Pharmacodynamics  
(PK/PD)
Colistin is commercially available as CMS (colistimeth-
ate sodium, colistin methanesulfate, pentasodium 
colistimethanesulfate, and colistin sulfonylmethate 
used for parenteral and inhalational use. CMS is an 
inactive prodrug of colistinand is less potent and 
less toxic than colistin sulphate; it differs from Poly-
myxin B only in amino acid components.Polymyxins 
are not absorbed by the gastrointestinal tract. For 
parenteral use, colistin should be diluted with 50 
ml of normal saline and infused over 30 minutes. 
In nebulizers, colistin is diluted with 4 mL of sterile 
water for injection or normal saline at a concentra-
tion of 250,000 IU/mL, then 2 mL is taken from the 
vial and further diluted with normal saline to make 
a final volume of 4-5 mL (125,000-100,000 units/
mL) of solution to fill the nebulizer. CMS would be 
hydrolyzed in aqueous solutions into the microbio-
logically active colistin; however liberation of colistin 
and the hydrolyzed complex mixture of partially sul-
fomethylated derivatives during storage may poten-
tiate the toxicity of CMS [13, 14, 15,16 ].
Colistin was evaluated in critically ill patients 
with MDR-GNB infections; itwas found to have 
a long half-life in relation to the 8 hourly dos-
ing intervals,this implies that dosing intervals may 
need adjustment and a loading dose is required to 
attain timely steady state level (17). CMS and colistin 
differ in their PK; CMS elimination involves renal 
tubular secretion, while colistin is mainly eliminated 
bypoorly understoodnon-renal mechanisms. Poly-
myxins distribution in most body organs is poor,and 
do not cross the blood-brain barrier in non-inflamed 
meninges. In multi-dose kinetics, CMS and poly-
myxin B attain good urine levels that exceed 15µg/
mL for at least 6 hours. Polymyxins serum levels are 
very low following inhalation therapy, and are poor-
ly dialyzed, have minimal hepatic metabolism or bili-
ary excretion [18]. Until now, there are no reliable 
PK models for polymyxin B that can generate the 
dose adjustments in patients with renal impairment. 
So, dose adjustments caughtin literature are based 
on some published studies as well as the recom-
mendations by manufacturers [16,18, 19]. However, 
interim population PK model for CMS and colistin 
in a population of critically ill patients with a wider 
range of renal dysfunction was evaluated to recom-
mend dosing [20].
The pharmacodynamic properties of colistin 
evaluatedwere minimal inhibitory concentration 
(MIC),bacterial-killing kinetics, and the post-antibi-
otic effect (PAE) against MDR-GNB. Colistin seems 
to be very active in the initial killing of A. baumannii, 
even with 0.5 × MIC, exhibiting a concentration-
dependent bacterial-killing mechanism; however 
the best parameter that correlate with colistin ac-
tivity is AUC/MIC (21). PAE of colistin was observed 
to be weak and clinically unattainable, high doses 
are needed to display the effect. Bacterial regrowth 
may occur during the PAE time period even when 
colistin was used as high as 64 × MIC. A. baumannii 
isolates with variable susceptibility to colistin, those 
that has been treated as colistin- monotherapy for 
extended-interval in ICU setting,and also septic pa-
tients withapparent colistin-susceptible strains that 
were treated with colistin may select out apopu-
lation of colistin-resistant strainsleading to clinical 
failure [19,22,23].
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Toxicity and adverse effects
A) Nephrotoxicity
The most common adverse effects of colistin ther-
apy is nephrotoxicity considering that drug excre-
tion is primarily by the kidneys, elevated blood lev-
els may further impair renal function. Renal toxicity 
mainly includes acute tubular necrosis manifested 
as increased serum urea and creatinine levels. Little 
information is available on the mechanism of toxic-
ity but in vitro electrophysiological studies demon-
strate that, at long exposure times, colistin is directly 
toxic to mammalian urothelium by increasing trans-
epithelial conduction [11,24].
A disparity between old and recent studies exists 
in the reported rates of nephrotoxicity associated 
with intravenous administration of colistin. A study 
in 1970 included 288 hospitalized patients with 317 
courses of CMS therapy were monitored for renal 
toxicity; renal injury occurred in about 20%and was 
reversible, deterioration of renal function occurred 
during colistin therapy; more in those patients with 
a history of renal failure [25, 26]. However, a large 
retrospective cohort study (2000 -2007) of 258 pa-
tients showed a relatively lower incidence of renal 
injury; as low as 10%(27).This can be clarified based 
on the use of more purified preparation, the use of 
CMS instead of colistin sulphate and dose adjust-
ment according to renal function (28).
B) Neurotoxicity
Neurological toxicities are considered to be dose-
dependent and usually reversible after early discon-
tinuation of colistin, it may present with different 
symptoms and signs; mainly dizziness, weakness, 
facial and peripheral paresthesia (commonest side 
effects), vertigo, visual disturbances, confusion and 
ataxia. Recent studies revealed a weak association 
between colistin treatment and neurotoxic events, 
some patients who develope colistin-suspected poly-
myoneuropathy had neurological symptoms before 
colistin was started [24]. Furthermore, myasthenia-
like syndrome or respiratory muscle paralysis produc-
ing apnoeaor respiratory failure occurred in 2.1% of 
patients, and typically in patients receiving colistin 
intramuscularly with renal failure, or treated with 
medications known to potentially induce respiratory 
muscle weakness (25). Earlier studies of cystic fibro-
sis patients demonstrated that development of neu-
rotoxic events related to colistin therapy appeared 
to occur more frequently, about 29%, but mostly 
mild like paresthesias [11]. The incidence of colistin-
associated neurotoxicity reported in the 1970’s was 
7.3%. The majority of adverse reactions occur dur-
ing the first 4 days of therapy, and in patients who 
received the recommended doses. Colistin therapy 
contributed to the death of 4.5% patients [25]. 
Other miscellaneous adverse reactions that have 
also been reported with the use of colistin include 
hypersensitivity reactions, skin rash, urticaria, gen-
eralized itching, fever, and mild gastro intestinal dis-
orders [11].
Parenteral colistin monotherapy
In an earlier study, colistin was used for non-critical-
ly ill paraplegic patients suffering from urinary tract 
infections caused by Klebsiella; it was used as a sal-
vage treatment after failure attempts with penicil-
lin, nitrofurantoin, tetracycline, Sulphadimidine, and 
streptomycin. Colistin was successful in Klebsiella 
treatment; however 11 of 18 (61.1%) patients had 
replacement with Proteus species [29].Later studies 
revealed that colistin do not coverProteus mirabilis 
and clinically cannot be used to treat this pathogen 
as shown inTable 1[30].
In critically ill patients,trials were held to evaluate 
colistin in a diversity of patients’ clinical scenarios;in 
a prospective, open-label, head-to-head study com-
paring colistin versus imipenem-cilastatin. Patients 
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with A. baumannii VAP were treated according to 
the antimicrobial susceptibility, after controlling for 
the acute and chronic health evaluation II (APACHE 
II) at the time of admission and sequential organ 
failure assessment (SOFA) scores at time of diagno-
sis. Cure rates were similar in both groups (57%) 
and in-hospital mortality rates (62 -64%). VAP-
attributable mortality and renal toxicity rates were 
comparable in both groups [31]. 
Inmostly trauma patients who develop commonly 
VAP and CLABSI caused by MDR-GNB but suscep-
tible to colistin, clinical response to colistin was ob-
served in 73%, and 30 days survival was 57.7% [32]. 
As salvage treatment colistin was used parentally 
in 23 patients with MDRP. aeruginosa infections; 
eighteen VAP and five cases of intra-abdominal 
infections;seven patients died, a favorable clinical 
response was observed in 14 patients (61%), 3 pa-
tients relapsed, associationwith bacteremia was the 
only significant factor related to treatment failure 
(P = 0.02) [33].
At the outset of the current MDR-GNB outbreak 
starting in the 2000’s, a group from Greece report-
ed a patient with septic shock due to MDR Klebsi-
ella pneumoniae who was successfully treated with 
intravenous colistin [34]. Latera prospective cohort 
two-armed study with mixed ICUpatients evaluat-
ing colistin efficacy against MDR-Acinetobacter 
baumannii and Pseudomonas aeruginosa, the most 
frequent infection was VAP; 53% in colistin group 
versus 66% in the other antimicrobials arm, Aci-
netobacter was the cause in 65% and 60% and 
Pseudomonas in 35% and 53% respectively. Pa-
tients were treated with colistin (n = 55) and other 
antimicrobialsmainly carbapenems (n = 130). Ad-
justed for age, APACHEII score, medical status, and 
SOFA score. Colistin appeared safe and as effec-
tive as other antimicrobials for treatment of sepsis 
caused by Acinetobacter and Pseudomonas in criti-
cally ill patients [35]. Aretrospective case series in 
general ICU encompassed 43 critically ill patients 
with infections due to MDR-Acinetobacter bauman-
nii and-Pseudomonas aeruginosa, mostly pneumo-
nia and bacteremia. Cases were reviewed to assess 
the effectiveness and safety of colistin; cure or im-
provement wasnoted in 74.4% of patients [26].
A case controlled, retrospective ICU studyfrom Tu-
nis comparedVAP treatment caused by pan-drug-
resistant Pseudomonas aeruginosaor Acinetobacter 
baumanii. Sixty colistin-treated patients matched to 
60 imipenem-treated patients with VAP caused by A. 
baumanii or P. aeruginosa susceptible to imipenem. 
The mean duration of antibiotic therapy for both 
antimicrobials were similar (p= 0.32). Favorable clini-
cal response occurred in 75% and 71.7% in the co-
listin group and in the imipenem group,respectively 
(p=0.68), and the time to resolution of infectious 
parameters after the initiation of antibiotic therapy 
was not statistically different [36].
Colistin was also evaluated retrospectively in 95 can-
cer patients;it was prescribedfor the treatment of 
MDRP. aeruginosa. Patients were treated with ei-
ther colistin (N = 31) or at least one active antipseu-
domonal agent (N = 64): a β-lactam or a quinolone. 
Though adjusted for APACHE II (score of >15, (P = 
0.074), colistin group contained more nosocomial 
infections (87% versus 64%, respectively; P = 0.02), 
the overall clinical response rates declaredas no sta-
tistical significant difference (52% versus 31%, P = 
0.055) [37].
Colistin in combination with other 
antimicrobial agents
Much like with using β-lactams monotherapy ver-
sus in combination with aminoglycosides,debate did 
not come to an end. In theory, combination aim 
is to maximize killing effect of pathogens, reduc-
ing rate of resistance,optimizing clinical outcome 
and reducing mortality [38]. However two earlier 
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meta-analyses published in 2003 and 2004 in BMJ 
addressing both immunocompetent andimmuno-
deficient febrile neutropenic patients. Both studies 
revealed that combination therapy did not change 
rates of fatality and increased adverse events [39,40].
Even the concept of reducing resistance among the 
causative pathogen did not prove legible; ameta-
analysis of eight randomized, controlled trials showed 
that β-lactam monotherapy versus aminoglycoside/
β-lactam combination was not found beneficial as 
far as the prevention of resistance against the initial-
ly used antimicrobial among treated susceptibleiso-
lates (P. aeruginosa, Pseudomonas species, Klebsi-
ella species, Proteus species, Acinetobacter species, 
and S. aureus, p ≥ 0.29 for the difference per each 
pathogen either treated with monotherapy or com-
bination therapy.Furthermore, the two regimens did 
not differ significantly in rates of treatment failure 
attributable to emergence of resistance, treatment 
failure attributable to superinfection, all-cause mor-
tality during treatment and mortality due to infec-
tion [38]. Another meta-analysis of 17 studies en-
compassing 3077 patients, mortality was evaluated 
for the antimicrobials monotherapy versus combina-
tion in the treatment of MDR-GNB bacteremia. It 
showed no survival benefit, except for infection by 
P. aeruginosa or other MDR-GNB infection; where 
more than one drug would be desirable to assure 
susceptibility of isolates to at least one antimicrobial 
agentinitially [41].
Colistin combination in vitro (Table 1)
Ever since the spread of MDR-GNB and the renais-
sance of colistin, the debate on monotherapy versus 
in combination with other agents came into view. 
Colistin was found to have some synergistic or ad-
ditive effect in vitro by combination with several 
agents e.g. rifampin, azithromycin, doxycycline, me-
ropenem, carbapenems and tigecycline [42]. An in 
vitro study of colistin efficacy alone or in combina-
tion with either ceftazidime, aztreonam, merope-
nem, gentamicin, piperacillin, ciprofloxacin, by using 
a distinct strain of P. aeruginosa; antimicrobials were 
tested at low and high concentrations. Addition of 
colistin to other antipseudomonal drugs tends to 
produce greater killing of P. aeruginosa than mono-
therapy (43). Furthermore, colistin in combination 
with rifampin showed a reasonable synergistic ef-
fect on MDR A. A. baumannii [44]. Nonetheless, 
another in vitro study examining the combination of 
colistin/tigecycline using MICs different folds inter-
actions with the checkerboard assay against thirty-
five isolates including Pan-Drug, X-Drug resistant, 
and imipenem-sensitive A. baumannii isolates; all 
tested strains displayed indifference [45].
Twelve KPCs collected from clinical isolates were 
evaluated for the activity of 2- and 3-drug combina-
tions including colistin, doripenem and ertapenem, 
all were resistant to ertapenem and doripenem; 
nine were colistin-resistant, belonged to the ST258 
and harbored blaKPC-2, blaSHV-12, and blaTEM-1. Co-
listin-ertapenem, colistin-doripenem, and colistin-
doripenem-ertapenem exhibited synergy against 
5/12, 6/12, and 8/12 of isolates, respectively. Levels 
of porin expression did not correlate with colistin-
doripenem or colistin-ertapenem synergy. However, 
synergy with colistin-doripenem-ertapenem was 
more likely against isolates with high porin expres-
sion than those with low expression 8/8 versus 0/4(P 
= 0.002) and greater bactericidal activity (P < 0.049) 
[46In a PK/PD model, a combination of colistin and 
rifampin against MDR A. baumannii, low (106) and 
high (108) concentration were used, the outcome 
was to investigate bacterial killing and emergence 
of colistin resistance. Both colistin susceptible and 
resistant strains were used. Against both strains; 
combinations resulted in substantially greater killing 
at the low inoculum. Emergence of colistin-resistant 
subpopulations was completely suppressed in the 
colistin-susceptible strains [47].
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Table 1. Studies that evaluated the outcome of colistin as monotherapy compared with the outcome of 
other commonly prescribed antimicrobial agents in different types of infections and microorganisms
Investigators
Type of 
study
Antimicrobial N Microorganisms Infection type outcome
Complication and 
Mortality
E. W. Colley et 
al (29)
Case series,  
salvage
Colistin 18 Klebsiella UTI paraplegia Success; All
11 replaced  with
 Proteus spp.
Nikolaos 
Markou et al 
(32)
Case series
Colistin 24 MDR-GNB VAP, CLABSI
Clinical 
response 73%
30-day 
Survival57.7%
Rosa Reina et 
al (35)
Prospective 
cohort
Colistin
Carbapenem
55
130
MDR-A. baumannii 
and P.  aeruginosa
Mixed 
ICU(mostly 
VAP)
Equally Effective Mortality; the same
M. E. Falagas 
et al (26)
Retrospective 
case series colistin 43
MDR-A. baumannii 
and P. aeruginosa
Bacteremia and 
VAP
Clinical 
response 74.4%
Deterioration of renal 
function occurred in 
18.6%
J. Garnacho-
Montero et al 
(31)
Prospective,  
open-label 
comparative
colistin versus 
imipenem-
cilastatin
21
14
A. baumannii VAP
Cure rates; 
similar in both 
groups (57%)
In-hospital mortality ; 
61.9% and 64.2%
VAP-attributable 
mortality; 38% & 
35.7%
Renal toxicity; 
comparable
Falagas ME et 
al (27)
retrospective 
cohort
Colistin 258 MDR-GNB
Mixed ICU 
patients
Cure of 
infection; 
79.1%
Nephrotoxicity; 10%  
Hospital survival; 
65.1%
Hachem RY et 
al (37)
Retrospective 
cohort, single 
center
Colistin versus 
Antipseudomonal 
β-lactams or 
quinolones
31
64
MDR-Pseudomonas 
aeruginosa
Cancer patients
52% vs. 31%
P = 0.055
Equally effective and 
safe
KPC: Carbapenemase-producing Klebsiella pneumoniae. MDR: Multi-drug resistant. GNB: gram-negative bacteria. VAP: Ventilator 
associated pneumonia. CLABSI: Central line-associated bloodstream infection. 
Colistin combination in vivo (Table 2)
Colistin was tested for use in cystic fibrosis patients 
harboring colistin-susceptible P. aeruginosa, doses 
of 2 million units, three times every twenty-four 
hours of intravenous colistin were used as mono-
therapy and in combination with other antimicro-
bial. In all cases there was significant improvement 
in the post-treatment versus pre-treatment forced 
expiratory volume in one second (p<0.0001) [48].
Matthew E. Falagas et al., retrospectively assessed 
colistin combination therapy intravenously for the 
management of several infections due to MDR-
GNB. Fifteen out of 50 patients were treated with 
colistin in combination with β-lactams, merope-
nem, ampicillin-sulbactam, aminoglycosides, and/
or quinolones. Clinical response of the infection 
(cure or improvement) was observed in 66.7%, and 
the effect of the combination treatment was not 
clear [50]. Another group from Italy used colistin in 
combination in 14 VAP patients with carbapenem-
resistant Acinetobacter baumanii; colistin-rifampin 
in eight patients and colistin-rifampin-ampicllin/sul-
bactam in six patients. Microbiological clearance of 
carbapenem-resistant A. baumannii infection took 
place in nine (64%). However, small size group and 
lack of a control group prohibit a definite conclusion 
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Table 2. Studies evaluating treatmentoutcome of colistin monotherapy versuscolistin in combination with 
different other antimicrobial agents in different types of infections and microorganisms
Investigators Type of study Antimicrobial N Microorganisms Infection type outcome
Other 
Comments
M. E. Falagas 
et al (50)
Retrospective 
cohort, single 
center
Colistin
vs. plus  meropenem, 
ampicillin-sulbactam, 
aminoglycosides, 
and/or quinolones
35
15
A.  baumannii
P. aeruginosa 
K. pneumoniae
Mixed
66.7% for all
Effect of 
combination 
was not clear
Colistin induced 
Renal injury (8%)
N. Petrosilloet 
al (50)
Case series
colistin-rifampin
vs.
 colistin-rifampin-
ampicllin/sulbactam
8
6
carbapenem-
resistant 
A.  baumanii
VAP and BSI
Effect of 
combination 
was not clear
Microbiological 
clearance  with 
combination was 
64%
YoheiDoi et al 
(52) 
Qureshi et al., 
(51)
Retrospective
Comparative
Colistin-Poly B vs.
Colistin-Poly B + 
carbapenem
41 KPC Bacteremia
Survival
Better in 
Combination 
(p=.02)
28-day Mortality 
Monotherapy = 
57.8%,
Plus carbapenem 
13.3%
(P= .01)
M. E. Falagas 
(50)
Retrospective 
cohort, Single 
center
colistin 
vs.
 colistin–meropenem 
14
57
MDR-GNB Mixed
No significant 
clinical-response 
differences 
were found (p = 
0.32)
On the contrary, 
a favorable 
clinical response 
for survival was 
with colistin 
monotherapy (p 
= 0.007), even 
after adjusting 
for confounders 
of colistin 
monotherapy
Falagas ME 
(27)
Retrospective 
cohort
Colistin 
vs.
Colistin plus other 
antimicrobial agents
25
8
Mixed
Clinical 
response 79.1% 
for all
Hospital 
survival is 
65.1%.Colistin-
meropenem 
better that other 
combinations
Pneumonia 
patients had 
better outcome 
than other 
infections
High colistin 
dose associated 
with less 
mortality
KPC: Carbapenemase-producing Klebsiella pneumoniae. Vs.: versus MDR: Multi-drug resistant. GNB: gram-negative bacteria. VAP: 
Ventilator associated pneumonia. BSI:Bloodstream infection. 
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about in vivo efficacy of combined therapy (50). A 
cohort of patients was retrospectively evaluated for 
the effectiveness of intravenous colistin monothera-
py versus colistin–meropenem combination therapy 
for patients with MDR-GNB infections. Fourteen 
patients received intravenous colist in monotherapy 
and 57 received colistin–meropenem. No significant 
clinical-response differences were found (p = 0.32). 
On the contrary, a favorable clinical response for 
survival was with colistin monotherapy (p = 0.007), 
even after adjusting for other variables that may 
skewed the results in favor of colistin monotherapy 
[51].
Colistin efficacy was evaluated for the site of in-
fection, the causative pathogen, dosage, as mono-
therapy versus combination therapy in a retrospec-
tive, cohort study of 258 patients. Cure of infection 
occurred in 79.1% of patients and hospital survival 
in 65.1%. Site of infection did not affect treatment 
outcome, nor was the type of pathogen. Patients 
who received colistin monotherapy or colistin/me-
ropenem combination had a better infection out-
come than those who received colistin in combina-
tion with other antibiotics (piperacillin/tazobactam, 
ampicillin/sulbactam and other agents). Moreover, 
patients with pneumonia had a better outcome 
compared with those with other infection types. 
Additionally, patients who received a higher average 
daily dose of colistin (9 million vs. 6 millions) had a 
lower mortality [27]
In a recent retrospective study, Yohei Doi and co-
workers Qureshi et al.,(51) compared 41 patients 
who receive either definitive therapy with colistin 
or tigecycline, as monotherapy and in combination 
with carbapenems for the treatment of bacteremia 
due to KPC-Klebsiella. The most commonly used 
combinations were colistin-polymyxin B or tigecy-
cline each combined with a carbapenem. The 28-
day mortality was 13.3% in the combination therapy 
group compared with 57.8% in the monotherapy 
group (P= 0.01). Overall mortality was 66.7% in the 
monotherapy group and 12.5% in the combination 
group [52].
Parenteral versus aerosolized use  
of colistin
Trials on animals using aerosolized colistin was 
promising, but randomized controlled clinical trials 
are lacking. In rats model two-thirds of aerosolized 
CMS dose is absorbed within the systemic circu-
lation and one-third is first converted into active 
colistin, thenis absorbed and its concentrations in 
epithelial lining fluid (ELF) were very high, enough 
to be active against the target microorganisms [53].
In humans, aerosolized colistin proved useful in 
cystic fibrosis and data compiled showing its ef-
fectiveness. In an earlier study, forty patients with 
cystic fibrosis with chronic P. aeruginosa pulmo-
nary infection were randomized into a prospective 
double-blind placebo-controlled study of colistin 
inhalation; colistin was dosed as one million units 
twice daily for three months versus is tonic saline. 
Interestingly, more patients in the colistin inhalation 
group completed the study (18 versus 11) and co-
listin treatment was superior to placebo treatment; 
better clinical symptom, maintenance of pulmonary 
function and inflammatory parameters [54].
Excluding cystic fibrosis patients, several studies at-
tempted to answer the question of clinical effec-
tiveness of aerosolized colistin in septic patients; 
a retrospective non-comparative study of aerosol-
ized colistin in 21 patients with MDR A. baumannii 
and P. aeruginosa pneumonia, three of whom had 
VAP. Overall clinical and microbiological response 
rates were 57.1% and 85.7%, respectively [55]. In a 
meta-analysis of five retrospective studies, aerosol-
ized colistin established itself as a reasonably safe 
alternative therapy for pneumonia and extra pul-
monary infections due to MDR P. aeruginosa or A. 
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baumannii. Hitherto, data on aerosolized form as 
adjunctive therapy are limited to allow its regular 
use in addition to systemic treatment [56].
Colistin was retrospectively reviewed in the man-
agement of 22 patients who were infected with 
metallo-β-lactamase (MBL)-producing P. aerugi-
nosa. Eleven of the patients received aerosolized 
colistin; Sixreceived solely aerosolize colistin had 
“favorable responses”. Eight of 12 patients treated 
with IV colistin had either full or partial response. 
This study revealed that intravenous colistin may be 
a useful drug when choices are limited, but aerosol-
ized colistin may not be reliable [57].
From January 2005 to December 2008 a retrospec-
tive case-control matching study with 0ne-to-one 
randomization was performed in Crete-Greece. ICU 
patients diagnosed with VAP and had cultures of 
monomicrobial colistin-susceptible A. baumanii, P. 
aeruginosa, or K. pneumoniae were included. Pa-
tients were analyzed if either received intravenous 
colistin or received intravenous combined with in-
halation colistin. No added therapeutic benefit 
whether clinical, microbiological, or survival benefit 
was observed for adding aerosolized colistin to in-
travenous regimen [58].
In the year 2012, Florescu and coworkers did a re-
view and meta-regression analysis, evaluating the 
efficacy and safety of intravenous and aerosolized 
colistin for the treatment of VAP compared with 
other antimicrobial agents [58]. Here, aerosolized 
colistin was used as an adjunctive agent to other 
antimicrobials in two of the six two-armed studies, 
and in seven of the fourteen single-arm studies, 
data implied that colistin can be an alternative treat-
ment for VAP caused by MDR-GNB (72% favorable 
clinical response rate and 34% in-hospital mortality 
comparable to rates reported in the literature). How-
ever, the authors did not suggest using this drug as 
first-line therapy, rather an alternative option when 
indicated, based on susceptibility reports.Therefore, 
no conclusion could be made on aerosolized colistin 
due to high studies heterogeneity [59].
Though aerosolized colistin is an attractiveoption for 
the treatment of MDR-GNB VAP or other systemic 
infections, it is not without added flaws, Burkhold-
eria cepacia, and Stenotrophomonas maltophilia 
are organisms that may cause pulmonary infec-
tions in cystic fibrosis, and colistin-resistant strains 
were found to contaminate 7/34 (20.6%)of colistin 
home-use nebulizers [60]. Furthermore, intravenous 
as well as aerosolized colistin administered sepa-
rately for sepsis induced respiratory failure as what 
followed in a case report of a 33-year-old woman 
who had second peripheral blood stem cell trans-
plant for acute myeloblastic leukemia [61].
Colistin: What is the proper dose?
Due to the fact that colistin is an ancient antimicro-
bial agent with uneven formulations; another look 
is needed to recommend a proper dose regimenin 
critically ill septic patients. Colistin potency is calcu-
lated and prescribe based on units/kg bodyweight/
day and on milligram/kg body weight/day basis in 
different countries. In USA the dose is based on 
the active drug component i.e. colistin base while 
in Europe “and probably the rest of the world” is 
based on the pro-drug CMS. Attention should be 
paid to dosing whether in milligram or units basis 
for both formulations.
The dosage of parenteral colistin recommended in 
the United States is 37,500 - 62,500 IU/kg/day (1mg 
colistin base = 2.4 mg of CMS = 30,000 IU) divided 
at 2 – 4 doses/day for patients with normal renal 
function, it should not exceed 62,500 IU/kg/day. In 
the United Kingdom the dosage recommended is 
50,000– 75,000 IU/kg/day in 3 divided doses for 
adults and children. For obese patients, the dose is 
recommended to be based on ideal body weight 
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[9, 10,11,62, 63].Critically septic patients have been 
treated with higher daily doses of intravenous colis-
tin; up to 9 million IU/day (720 mg)in 3 divided doses 
[64,65]. Another study evaluating “High” dose co-
listin for the clinical outcome and renal injury in 28 
infectious episodes in critically ill patients, episodes 
were due to A.baumannii (46.4%), K. pneumoniae 
(46.4%), and P. aeruginosa (7.2%); bloodstream in-
fection (64.3%), VAP (35.7%); doses used were; a 
loading dose of 9 million IU and a 4.5-million IU 
twice-daily as a maintenance dose. Colistin doses 
were adjusted according Cockcroft-Gault creatinine 
clearance estimates, patients with creatinine clear-
ance<50 mL/min, a loading dose of 9 million IU and 
maintenance doses was administered for all; a main-
tenance of 4.5 million IU every12 hours for clear-
ance >50%, for 20–50 mL/min 4.5 million IU every 
24 hours and for <20 mL/min the maintenance dose 
was 4.5 million IU every 48 hours. In patient under-
going hemodialysis the recommended intravenous 
dosage of CMS are 25,000- 37,500 IU/kg after each 
hemodialysis and 25,000 IU/kg daily during perito-
neal dialysis. The recommended aerosolized dose 
is 500,000 IU every 12 hours, for patient <40 kg, 
and 1 million every 12 hours for patients >40 kg. 
(66, 67) Clinical cure attained was 82.1% (23 pa-
tients), and acute renal insult developed in 17.8% 
(5 patients) but subsided within 10 days from CMS 
discontinuation [68].
In a retrospective study in 76 patients with MDR-
GN bacteremia, evaluating the association between 
CMS dose and day-7 microbiological success, as 
the primary outcome measure, mortalities on day-
7 andday-28 and acute kidney injury as secondary 
outcome measures. The median colistin dose was 
significantly higher in patients who achieved micro-
biological success (37,500 vs 18,750 IU/kg/day; P = 
.011), independently correlated with microbiologi-
cal success (AOR = 1.74; P = .015) and significantly 
higher survivors at day 7 (37,500 vs 18,750 IU/kg/
day; P = .007), but no difference was observed four 
weeks later. Acute kidney injury significantly was as-
sociated with higher colistin dose (47,500 vs 20,000 
IU/kg/day; P < .001) [69].
To eliminate confusion about colistin dose, and to 
make more sense of comparing future studies,we 
need to standardize our prescription dose and di-
mensions; units or milligram, preferably in units (IU). 
Formulations may differ if prescribed on milligram 
bases while using IU should be similar among all 
(63). Furthermore, doses to be calculated should be 
based on the ideal body weight (IBW), or dosing 
body weight (DBW) in kilograms. DBW is calculated 
according to the formula: DBW = IBW + 0.4(ABW– 
IBW) in case that thatpatients’ actual body weight 
≥ 130% of their IBW [69].
Future pressing issues
The continued emergence and complexity of bac-
terial resistance are of great concern and threat to 
human health. New effective and minimally toxic 
antimicrobial agents directed against MDR-GNB are 
needed. Discovery of new antimicrobial agents is 
currently compromised, in the 1980’s there were 
16 newly introduced antimicrobial agents, while in 
1998 – 2002 only 6 agents were introduced, and 
the last decade only 4 agents found their way to 
the market [70,71]. At present colistin either mono-
therapy or combined with other agents should be 
prescribed prudently to combat infections resulting 
from these notorious microorganisms, to avoid and 
slow the unavoidable resistance to colistin. A prudent 
use of antimicrobials based on their patterns may 
help in this issue e.g. molecular characterization of 
KPCK. pneumoniae isolates may be a practical tool 
for identifying effective combination regimens as 
well as de-escalation when possible, and optimizing 
colistin-combination against colistin-susceptible and 
-resistant MDR-GNB [45, 46]. A beneficial effect of 
combination therapy with colistin was not clearly 
demonstrated either for clinical response or sur-
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vival(48,49,50). On the contrary, a favorable clinical 
response for survival was demonstrated in a study 
with colistin monotherapy (p = 0.007), even after 
adjusting for other variables that may have skewed 
the results in favor of colistin monotherapy [51].
Conclusion
While probing for newer agents and or concepts 
that combat MDR-GNB, several methods may be 
employed to decrease this burden by adopting in-
fection control measures; hand washing, isolating 
or cohorting patients with MDR-GNB infections. 
However colistin will stay the agent of choice for 
MDR-GNB in the near foreseen future [72, 73,74].
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